Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.

Risk factors for relapse after discontinuation of antiepileptic drugs

06 Aug 2017

Patients receiving more than one antiepileptic drug (AED) and who had started AED treatment more than 6 months after the first syndrome are at a higher risk of recurrence after discontinuation of medication, a new study has shown.

Of 292 epileptic patients who had been seizure-free for more than 2 years, 97 continued AED while 195 were withdrawn from AED treatment. Among patients who ceased AED treatment, 119 had relapsed, resulting in a relapse rate of 34.4 per 100 person-years.

Compared with patients who did not relapse, those who received first treatment more than 6 months after epilepsy diagnosis (p=0.021) and who had an established aetiology (p=0.03) had significantly higher risks of relapse.

Patients who received more than one type of AED before discontinuation (p=0.083), who were not immediately seizure-free after AED initiation (p=0.063) and who changed AED regimens (p=0.070) were at moderately elevated risks of relapse.

Cox proportional hazard regression showed that those who received more than one type of AED drug (hazard ratio [HR], 2.53; 95 percent CI, 1.24 to 5.16; p=0.011) and whose epilepsy was more than 6 months long before AED initiation (HR, 1.47; 1.004 to 2.15; p=0.048) had higher risks of recurrence after AED withdrawal.

Study participants were recruited from the Department of Neurology in Huashan hospital in Shanghai, China. Epilepsy patients were followed-up through interviews, telephone conversations and medical records.

Only patients between the ages of 14 and 80 years, who had received stable doses of one or two AEDs, and who were seizure-free for at least 2 years were included. Exclusion criteria was a history of irregular AED treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.